Neurology Xagena
A Phase II study of Rituximab ( MabThera, Rituxan ) for relapsing-remitting multiple sclerosis ( RRMS ) met its primary endpoint. The study of 104 patients showed a statistically significant reductio ...
A drug therapy currently used to treat non-Hodgkins lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical t ...
A drug therapy currently used to treat non-Hodgkins lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical t ...
A drug therapy currently used to treat non-Hodgkins lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical ...
A previous 2-year analysis of repeated Rituximab ( MabThera, Rituxan ) treatment in patients with neuromyelitis optica ( NMO ) revealed significant improvements in relapse rates and disability.Researc ...
More than 80% of individuals with multiple sclerosis ( MS ) experience a relapsing-remitting disease course. Approximately 10 years after disease onset, an estimated 50% of individuals with relapsing- ...
Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more than two months. ...
Rituximab ( MabThera, Rituxan ) is a chimeric murine/human monoclonal antibody that specifically targets CD20 molecules on the surface of B-cells, thereby depleting B-cells and regulating humoral immu ...
New disease-modifying treatment strategies in multiple sclerosis offer possibilities for individualised treatment. In a study, researchers evaluated patient-reported outcome measures before and afte ...
